Fundz

Accu Vein Inc. reported raising $8 Million in an initial SEC Form D filing, from an offering of $10 Million

PRIVATEFeb 12, 2018$8M of $10M raised

Amount Raised

$8 Million

$8 Million sold, per SEC Form D (first sale Feb 12, 2018)

Round Type

Venture

New YorkHealthcare

Quick answer

AccuVein Inc. raised $8 Million in a funding round, dated February 12, 2018. AccuVein Inc. is based in New York, United States.

How much did AccuVein Inc. raise?
AccuVein Inc. raised $8 Million in a funding round on February 12, 2018.
What does AccuVein Inc. do?
AccuVein Inc. is the global leader in vein illumination.
Where is AccuVein Inc. based and how big is it?
AccuVein Inc. is based in New York, United States.

Source: Fundz verified event record.

Who else raised in Healthcare around the same time

Companies in the same sectors as AccuVein Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Praxis Precision Medicines, Inc. raised $19M on March 26, 2018.
  • Purple Biotech raised an undisclosed amount on March 26, 2018.
  • Pneuma Respiratory raised $6M on March 23, 2018.
  • Can-Fite BioPharma Ltd. raised $5M on March 22, 2018.
  • VenoStent raised $70K on March 22, 2018.
  • MindChild Medical, Inc raised $210K (Seed) on March 22, 2018.

Who to call at AccuVein Inc., and when

A new round usually means AccuVein Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day AccuVein Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at AccuVein Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at AccuVein Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

AccuVein Inc.

Location

3243 ROUTE 112, BUILDING 1, SUITE 2

New York, United States

About

AccuVein Inc. is the global leader in vein illumination. The AV400 vein illumination system allows health care professionals to see a map of peripheral veins on the skin’s surface with the goal of improving vascular access procedures including blood draw, IV infusion and blood donation as well as for avoiding veins for cosmetic injectable procedures. To see a demonstration of AccuVein in action, please visit www.accuvein.com or call 877-772-5607. 
AccuVein is the world’s only portable, non-contact vein illumination solution. AccuVein is in use at more than 3,000 hospitals and available for sale in over 100 countries worldwide. An Essential Tool The AccuVein AV400 displays a map of the vasculature on the surface of the skin.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment AccuVein Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for AccuVein Inc.'s next move

See what Strategic adds

AccuVein Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.